Mylan Generics Company Intelligence Report

Summary

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Contents

• Executive Summary
• Introduction
  • Mylan to retain Dey subsidiary
  • Products
  • ANDA Approvals
  • Mylan ANDA Approvals, 2002-09
  • Matrix Laboratories ANDA Approvals, 2002-09
  • Merck Generics subsidiary ANDA Approvals
  • Alphapharm ANDA Approvals, 2002-09
  • Dey ANDA Approvals, 2002-07
  • Genpharm ANDA Approvals, 2002-09
  • Recent product approvals
  • Emtricitabine / tenofovir (tentative) (Matrix)
  • Lopinavir / ritonavir (Matrix)
  • Divalproex
  • Lamotrigine
  • Omeprazole
  • Stavudine (Matrix)
  • Fluoxetine
  • Venlafaxine hydrochloride (tentative)
  • Levetiracetam
  • Olmesartan medoxomil and hydrochlorothiazide (tentative)
  • Alfuzosin (tentative)
  • Carbidopa and levodopa
  • Mylan receives FDA approval for generic Risperdal Tablets
  • Nisoldipine
  • Linezolid (tentative)
  • Irbesartan+hydrochlorothiazide (tentative)
  • Nevirapine (tentative) (Matrix)
  • Paroxetine extended-release
  • Ropinirole
  • Trandolapril tablets
  • Felodipine extended-release tablets
  • Granisetron tablets
• MYLAN GENERIC COMPANIES ANALYSIS
  • Financial results
  • Latest Quarterly Revenues, Q408
  • Mylan: fourth quarter FY08 financial data, in US$000s
  • Latest Fiscal Year Results, 2008
  • Mylan: full year results, 2005-08, in US$ millions
  • Segment Data
  • Mylan: segment results, 2007-2008, in US$000s
• Major developments
  • Matrix Laboratories
  • Mylan downsizes Puerto Rico facility
  • Mergers, acquisitions and agreements
  • Mylan signs OC agreement with Famy Care
  • Forest Laboratories
  • Merck Generics
  • Litigation
  • Mylan announces desloratadine settlement
  • Galderma files lawsuit against Mylan
  • Sepracor files eszopiclone patent infringement lawsuits
  • OSI files lawsuits against Teva and Mylan
  • Shire files lanthanum patent infringement lawsuit against Mylan
  • Daiichi Sankyo files patent infringement actions in Japan over generic levofloxacin
  • Dey settles Mississippi pricing litigation
  • Takeda wins attorney's fee in patent case against Mylan and Alphapharm
  • Warner Chilcott/Mayne file lawsuits for infringement of Doryx patent
  • Mylan/Novartis enter agreement to settle Femara patent challenge
  • Cephalon/Eurand file patent infringement lawsuit against Mylan and Barr over generic Amrix
  • Court favours Barr and Mylan in galantamine case
  • Daiichi Sankyo sues Matrix for Azor patent infringement
  • FTC files complaint against Cephalon charging unlawful blockage of generic modafinil
  • Forest and Merz file second suit against memantine challengers
  • Mylan to appeal latest lorazepam and clorazepate ruling
  • Contact Details